Clinical Trials Directory

Trials / Completed

CompletedNCT03568435

Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Efficacy and Safety of Nivolumab in Metastatic Renal Cell Cancer Patients - Japanese Real-World Data Through Clinical Chart Review

Status
Completed
Phase
—
Study type
Observational
Enrollment
212 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
—
Healthy volunteers
Not accepted

Summary

A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer

Conditions

Interventions

TypeNameDescription
OTHERNon-InterventionalNon-Interventional

Timeline

Start date
2018-02-14
Primary completion
2020-12-21
Completion
2020-12-21
First posted
2018-06-26
Last updated
2022-10-20

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT03568435. Inclusion in this directory is not an endorsement.